Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRIO NASDAQ:LUCD NASDAQ:PDEX NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$7.44-2.2%$7.71$5.93▼$17.74$55.57M1.117,587 shs5,149 shsLUCDLucid Diagnostics$0.97-5.2%$1.10$0.90▼$1.63$207.13M1.08957,149 shs858,195 shsPDEXPro-Dex$65.21-2.7%$56.16$23.47▼$68.99$213.91M-0.0238,038 shs67,026 shsTMCITreace Medical Concepts$3.51-4.9%$2.21$1.17▼$7.78$239.38M1.4651,937 shs492,135 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth-0.65%+1.06%-4.88%-21.65%-45.40%LUCDLucid Diagnostics+1.49%-2.86%-6.42%-27.14%-16.39%PDEXPro-Dex+2.81%-0.74%+19.64%+47.94%+62.42%TMCITreace Medical Concepts+8.53%+19.81%+96.28%+158.04%-36.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$7.44-2.2%$7.71$5.93▼$17.74$55.57M1.117,587 shs5,149 shsLUCDLucid Diagnostics$0.97-5.2%$1.10$0.90▼$1.63$207.13M1.08957,149 shs858,195 shsPDEXPro-Dex$65.21-2.7%$56.16$23.47▼$68.99$213.91M-0.0238,038 shs67,026 shsTMCITreace Medical Concepts$3.51-4.9%$2.21$1.17▼$7.78$239.38M1.4651,937 shs492,135 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth-0.65%+1.06%-4.88%-21.65%-45.40%LUCDLucid Diagnostics+1.49%-2.86%-6.42%-27.14%-16.39%PDEXPro-Dex+2.81%-0.74%+19.64%+47.94%+62.42%TMCITreace Medical Concepts+8.53%+19.81%+96.28%+158.04%-36.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRIODarioHealth 2.00Hold$10.5041.22% UpsideLUCDLucid Diagnostics 2.60Moderate Buy$4.13326.49% UpsidePDEXPro-Dex 2.33Hold$70.007.35% UpsideTMCITreace Medical Concepts 1.86Reduce$4.7735.90% UpsideCurrent Analyst Ratings BreakdownLatest DRIO, TMCI, PDEX, and LUCD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026PDEXPro-Dex Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LUCDLucid Diagnostics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/15/2026LUCDLucid Diagnostics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.505/14/2026DRIODarioHealth Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00 ➝ $10.005/13/2026DRIODarioHealth TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$11.005/12/2026PDEXPro-Dex Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.005/6/2026LUCDLucid Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/1/2026PDEXPro-Dex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/20/2026TMCITreace Medical Concepts Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026LUCDLucid Diagnostics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.25 ➝ $9.003/30/2026LUCDLucid Diagnostics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.50(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRIODarioHealth$22.36M2.43N/AN/A$10.05 per share0.74LUCDLucid Diagnostics$4.71M41.70N/AN/A($0.31) per share-3.12PDEXPro-Dex$66.59M3.12$3.05 per share21.37$11.23 per share5.81TMCITreace Medical Concepts$212.69M1.07N/AN/A$1.37 per share2.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRIODarioHealth-$41.71M-$8.88N/AN/AN/A-192.23%-60.52%-37.08%8/11/2026 (Estimated)LUCDLucid Diagnostics-$58.01M-$0.47N/AN/AN/A-876.72%N/A-116.26%8/12/2026 (Estimated)PDEXPro-Dex$8.98M$3.6218.0123.46N/A16.08%22.78%14.30%7/8/2026 (Estimated)TMCITreace Medical Concepts-$59M-$0.97N/AN/AN/A-29.44%-67.04%-30.28%8/6/2026 (Estimated)Latest DRIO, TMCI, PDEX, and LUCD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LUCDLucid Diagnostics-$0.05-$0.07-$0.02-$0.17$1.38 million$1.26 million5/8/2026Q1 2026TMCITreace Medical Concepts-$0.31-$0.28+$0.03-$0.28$45.96 million$47.20 million4/30/2026Q3 2026PDEXPro-Dex$0.62$1.20+$0.58$1.20$17.90 million$19.95 million3/25/2026Q4 2025LUCDLucid Diagnostics-$0.07-$0.10-$0.03-$0.12$1.39 million$1.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRIODarioHealthN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRIODarioHealth0.503.072.62LUCDLucid DiagnosticsN/A1.071.05PDEXPro-Dex0.323.672.14TMCITreace Medical Concepts0.723.582.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRIODarioHealth33.39%LUCDLucid Diagnostics74.01%PDEXPro-Dex15.28%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipDRIODarioHealth3.50%LUCDLucid Diagnostics6.80%PDEXPro-Dex45.90%TMCITreace Medical Concepts23.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRIODarioHealth2007.31 million7.06 millionNo DataLUCDLucid Diagnostics70203.07 million189.26 millionNo DataPDEXPro-Dex1403.19 million1.73 millionNot OptionableTMCITreace Medical Concepts25064.87 million49.68 millionOptionableDRIO, TMCI, PDEX, and LUCD HeadlinesRecent News About These CompaniesTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 50,000 SharesJune 2 at 4:58 AM | insidertrades.comTreace Medical Concepts Balances Growth With Earnings StrainJune 1, 2026 | tipranks.comJohn Treace Purchases 4,508 Shares of Treace Medical Concepts (NASDAQ:TMCI) StockMay 29, 2026 | insidertrades.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Rating of "Reduce" from AnalystsMay 28, 2026 | americanbankingnews.comWilliam Blair Investment Management LLC Sells 2,488,883 Shares of Treace Medical Concepts, Inc. $TMCIMay 27, 2026 | marketbeat.comTreace Medical Shareholders Back Directors, Pay and AuditorMay 20, 2026 | tipranks.comTreace Medical Concepts, Inc.May 15, 2026 | edition.cnn.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 43,000 SharesMay 15, 2026 | insidertrades.comTreace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 12, 2026 | globenewswire.comTreace Medical Concepts Inc (TMCI) Q1 2026 Earnings Call Highlights: Navigating Revenue ...May 9, 2026 | finance.yahoo.comTreace Medical Concepts Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comTreace Medical Concepts (NASDAQ:TMCI) Issues Quarterly Earnings ResultsMay 8, 2026 | marketbeat.comTreace Medical Concepts: Q1 Earnings SnapshotMay 8, 2026 | myjournalcourier.comMTreace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue EstimatesMay 8, 2026 | zacks.comTreace Medical Concepts Reports First Quarter 2026 Financial ResultsMay 8, 2026 | globenewswire.comTreace Medical Concepts Inc (TMCI) Q1 2026 Earnings Report Preview: What To ExpectMay 7, 2026 | finance.yahoo.comHow The Treace Medical Concepts (TMCI) Story Is Shifting With Mixed Analyst ExpectationsMay 3, 2026 | finance.yahoo.comTreace Medical Concepts, Inc. to Release First Quarter 2026 Financial Results and Host Conference CallApril 24, 2026 | quiverquant.comQTreace to Report First Quarter 2026 Financial Results on May 8, 2026April 24, 2026 | globenewswire.comHow The Treace Medical Concepts (TMCI) Narrative Is Shifting With New Targets And Product PlansApril 18, 2026 | finance.yahoo.comTreace Medical Concepts Announces Leadership Transition and OutlookApril 11, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRIO, TMCI, PDEX, and LUCD Company DescriptionsDarioHealth NASDAQ:DRIO$7.44 -0.17 (-2.17%) Closing price 03:58 PM EasternExtended Trading$7.47 +0.04 (+0.47%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Lucid Diagnostics NASDAQ:LUCD$0.97 -0.05 (-5.18%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.02 (+2.56%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Pro-Dex NASDAQ:PDEX$65.21 -1.79 (-2.67%) Closing price 04:00 PM EasternExtended Trading$65.70 +0.49 (+0.75%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Treace Medical Concepts NASDAQ:TMCI$3.51 -0.18 (-4.88%) Closing price 04:00 PM EasternExtended Trading$3.67 +0.16 (+4.53%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
